Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

4.784 -0.286 (-5.64%)
Streaming Delayed Price Updated: 2:43 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,031
Open 5.030
Bid (Size) 4.770 (33)
Ask (Size) 4.890 (1)
Prev. Close 5.070
Today's Range 4.760 - 5.069
52wk Range 4.970 - 14.36
Shares Outstanding 37,950,986
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bolt Revenue Jumps 39 Percent in Q2
Via The Motley Fool
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-58.0%
-58.0%
1 Month
-16.6%
-16.6%
3 Month
-27.0%
-27.0%
6 Month
-51.3%
-51.3%
1 Year
-65.4%
-65.4%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Via Chartmill
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Participate in Upcoming March Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces Changes to its Board of Directors
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bolt Biotherapeutics to Participate in Upcoming September Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Frequently Asked Questions

Is Bolt Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Bolt Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Bolt Biotherapeutics, Inc. - Common Stock trade on?
Bolt Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock is BOLT on the Nasdaq Stock Market
What is the current price of Bolt Biotherapeutics, Inc. - Common Stock?
The current price of Bolt Biotherapeutics, Inc. - Common Stock is 4.784
When was Bolt Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Bolt Biotherapeutics, Inc. - Common Stock was at 08/19/25 02:43 PM ET
What is the market capitalization of Bolt Biotherapeutics, Inc. - Common Stock?
The market capitalization of Bolt Biotherapeutics, Inc. - Common Stock is 181.55M
How many shares of Bolt Biotherapeutics, Inc. - Common Stock are outstanding?
Bolt Biotherapeutics, Inc. - Common Stock has 182M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.